Licensing strategies are vital in avoiding portfolio or pipeline standstill. Consequently, drivers and resistors of licensing deals must be evaluated, and relationships with small pharma, biotech companies and academia must be built up and maintained. At the conference, 12 case studies and two panel discussions will illustrate the following topics:
• Relationship of R&D with business development
• Structure and procedure of licensing strategies
• Financial aspects of licensing: new partnerships and alternative deal-making, i.e. Alliance Management
Meet representatives of major market players at the conference, e.g. Bayer HealthCare, F. Hoffmann La Roche, Novartis Pharma, AstraZeneca UK and many more. For an interactive exchange of information, conference participants have the opportunity to attend the following workshops on Wednesday, 25 April 2012:
• “Licensing Trends – Success of licensing activity and beyond”
• “Strategic licensing as a cost-effective means”
• “Key legal fields affecting the life science sector in licensing”
• “Strategies at the edge of patent life”
Many networking breaks throughout the conference days give participants the opportunity to reach out and discuss their respective challenges and fields of interested.
For more information and interesting downloads, check
http://bit.ly/...